Treatment of acute cluster headache with sumatriptan
- PMID: 1647496
- DOI: 10.1056/NEJM199108013250505
Treatment of acute cluster headache with sumatriptan
Abstract
Background: Attacks of cluster headache are difficult to treat. Sumatriptan, an agonist of 5-hydroxytryptamine1-like receptors, has proved effective in the treatment of migraine. The clinical similarities between migraine and cluster headache and positive results from an open pilot study in patients with cluster headache indicated that sumatriptan should be evaluated more rigorously in the treatment of this condition.
Methods: We conducted a randomized, double-blind, placebo-controlled crossover study to assess the efficacy and tolerability of sumatriptan in 49 patients with cluster headache. The patients received, in random order, a subcutaneous injection of 6 mg of sumatriptan for one cluster-headache attack and placebo for another attack. The results for the two attacks could be fully evaluated for 39 patients. A response to treatment was defined as complete or almost complete relief of headache (no pain or mild pain) within 15 minutes after the injection.
Results: In the 39 patients, the severity of headache decreased in 74 percent of the attacks within 15 minutes of treatment with sumatriptan, as compared with 26 percent of the attacks for which placebo was given (P less than 0.001). Thirty-six percent of the patients were free of pain within 10 minutes after the administration of sumatriptan, as compared with 3 percent after placebo (P less than 0.001); by 15 minutes these numbers had increased to 46 percent and 10 percent, respectively (P less than 0.001). Thirteen percent of the patients required oxygen as an additional treatment 15 minutes after receiving sumatriptan, as compared with 49 percent of those who received placebo. The severity of functional disability and the incidence of ipsilateral conjunctival injection also decreased more in response to sumatriptan than placebo. Sumatriptan was well tolerated, and there were no serious adverse events.
Conclusions: Sumatriptan is an effective and well-tolerated treatment for acute attacks of cluster headache.
Comment in
-
Serotonin receptors and headache.N Engl J Med. 1991 Aug 1;325(5):353-4. doi: 10.1056/NEJM199108013250509. N Engl J Med. 1991. PMID: 1647497 No abstract available.
Similar articles
-
Treatment of migraine attacks with sumatriptan.N Engl J Med. 1991 Aug 1;325(5):316-21. doi: 10.1056/NEJM199108013250504. N Engl J Med. 1991. PMID: 1647495 Clinical Trial.
-
Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. The Sumatriptan Cluster Headache Study Group.Acta Neurol Scand. 1993 Jul;88(1):63-9. doi: 10.1111/j.1600-0404.1993.tb04189.x. Acta Neurol Scand. 1993. PMID: 8396833 Clinical Trial.
-
Subcutaneous sumatriptan in acute treatment of migraine: a multicentre New Zealand trial.N Z Med J. 1993 May 12;106(955):171-3. N Z Med J. 1993. PMID: 8389026 Clinical Trial.
-
Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache.Drugs. 1994 Apr;47(4):622-51. doi: 10.2165/00003495-199447040-00006. Drugs. 1994. PMID: 7516861 Review.
-
Clinical effects and mechanism of action of sumatriptan in migraine.Clin Neurol Neurosurg. 1992;94 Suppl:S73-7. doi: 10.1016/0303-8467(92)90028-2. Clin Neurol Neurosurg. 1992. PMID: 1320526 Review.
Cited by
-
Use of Prescribed and Non-Prescribed Treatments for Cluster Headache in a Swedish Cohort.Brain Sci. 2024 Mar 31;14(4):348. doi: 10.3390/brainsci14040348. Brain Sci. 2024. PMID: 38672000 Free PMC article.
-
Commentary on 2022 guidelines on clinical trial design in cluster headache and further suggestions.J Headache Pain. 2024 Mar 7;25(1):32. doi: 10.1186/s10194-024-01732-3. J Headache Pain. 2024. PMID: 38454380 Free PMC article.
-
Patients with chronic cluster headache may show reduced activity energy expenditure on ambulatory wrist actigraphy recordings during daytime attacks.Brain Behav. 2024 Jan;14(1):e3360. doi: 10.1002/brb3.3360. Brain Behav. 2024. PMID: 38376015 Free PMC article.
-
Baseline demographics and disease characteristics of patients with episodic or chronic cluster headache: data from two phase 3 randomized clinical trials in Europe and North America.Front Neurol. 2023 Dec 15;14:1293163. doi: 10.3389/fneur.2023.1293163. eCollection 2023. Front Neurol. 2023. PMID: 38162453 Free PMC article.
-
Cluster headache: state of the art in treatment.Front Pain Res (Lausanne). 2023 Oct 27;4:1265540. doi: 10.3389/fpain.2023.1265540. eCollection 2023. Front Pain Res (Lausanne). 2023. PMID: 37965210 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources